Ancillary Symposium: New Horizons for Medical Management of Acromegaly

show details hide details

login required

play

Not Currently Available

Landscape: What’s New and What’s Changed

Shlomo Melmed, MB ChB

Cedars-Sinai Medical Center, Los Angeles, California, USA

Shlomo Melmed, MB ChB, is Executive Vice-President and Dean at Cedars-Sinai Medical Center and holds the Helene A. and Philip E. Hixon Chair in Investigative Medicine. He has been a recipient of the Endocrinology Medal of the Royal Society of Medicine, the Endocrine Society Clinical Investigator and Outstanding Scholarly Physician Awards, the Society of Endocrinology Transatlantic Medal, the Fondation IPSEN Endocrine Regulations Prize, and the Pituitary Society's Lifetime Achievement Award. Dr. Melmed’s research is devoted to molecular pathogenesis and treatment of pituitary tumors and growth factor regulation of anterior pituitary function. He edits The Pituitary and co-edits Williams Textbook of Endocrinology; he co-authors Harrison's Textbook of Medicine pituitary section, is editor-in-chief of Pituitary, and is on the editorial board of Journal of Clinical Investigation and past Editor-in-Chief of Endocrinology. He served on NIH Endocrinology Study Section, was president and founding member of the Pituitary Society, member of Endocrine Society Council and President of International Society of Endocrinology. He is Program Chair of the International Congress of Endocrinology, and a Board Member of the California Institute of Regenerative Medicine (CIRM).

Disclosures:

Consultant, Chiasma Inc, Ionis, Crinetics, Ipsen; Research Grant Support, Pfizer

Expanding View: Understanding Patients’ Treatment Burden and Experience

Eliza B. Geer, MD

Memorial Sloan Kettering Cancer Center, New York, New York, USA

Eliza B. Geer, MD, joined the faculty at The Mount Sinai Medical Center in July, 2006 with an appointment in the Division of Endocrinology and a secondary appointment in the Department of Neurosurgery. After graduating from Columbia University, she attended Mount Sinai School of Medicine, graduating with Distinction in Research. She completed her Internship and Residency in Internal Medicine at Columbia Presbyterian Medical Center, where she became involved in neuroendocrine research, conducting studies on the hypothalamic-pituitary-adrenal axis and acromegaly. After completing her residency, she conducted a year of clinical research at Columbia's Obesity Research Center, funded by a NIH T32 grant, where she focused on body composition and appetite in acromegaly. She then completed a fellowship in Endocrinology, Diabetes and Bone Disease at the Mount Sinai Medical Center, graduating in 2006.

Disclosures:

Research Support, Novartis, Strongbridge, Chiasma, Ionis, Bristo-Myers Squibb; Consultant, Chiasma; Advisory Board, Strongbridge

A New Horizon: Treatment Options for Optimal Outcomes

Lawrence Katznelson, MD

Stanford School of Medicine, Stanford, California, USA

Laurence Katznelson, MD, received his medical degree from the University of California, Los Angeles and performed his internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania, Philadelphia. He then performed a fellowship in Endocrinology and Metabolism at the Massachusetts General Hospital, Boston. Dr. Katznelson is a Professor of Neurosurgery and Medicine at Stanford University School of Medicine. At Stanford University, he is the Associate Dean of Graduate Medical Education and the Chair of the GME Committee. Dr. Katznelson is currently the Medical Director of the Pituitary Center at Stanford Hospital and Clinics. In the Endocrine Society, Dr. Katznelson has served as Chair of the Special Programs and Nominations Committees. He has served as Chair of the Task Forces for writing clinical guidelines for the approach to acromegaly for both The Endocrine Society and the American Association of Clinical Endocrinologists. Dr. Katznelson has also served as Chair of the Clinical Investigator Workshop for the Endocrine Society. He is the recipient of the 2017 Laureate Award for Educator of the Year, The Endocrine Society. He is also the recipient of the H. Jack Baskin, Endocrine Teaching Award, AACE in 2015. Dr. Katznelson has a long standing clinical and research interest in the pathophysiology and treatment of pituitary disease.

Disclosures:

Research Grant Support, Chiasma Inc.; Advisory Board, Pfizer

The Journey: How to Proceed, the Decision Process

Shlomo Melmed, MB ChB

Cedars-Sinai Medical Center, Los Angeles, California, USA

Shlomo Melmed, MB ChB, is Executive Vice-President and Dean at Cedars-Sinai Medical Center and holds the Helene A. and Philip E. Hixon Chair in Investigative Medicine. He has been a recipient of the Endocrinology Medal of the Royal Society of Medicine, the Endocrine Society Clinical Investigator and Outstanding Scholarly Physician Awards, the Society of Endocrinology Transatlantic Medal, the Fondation IPSEN Endocrine Regulations Prize, and the Pituitary Society's Lifetime Achievement Award. Dr. Melmed’s research is devoted to molecular pathogenesis and treatment of pituitary tumors and growth factor regulation of anterior pituitary function. He edits The Pituitary and co-edits Williams Textbook of Endocrinology; he co-authors Harrison's Textbook of Medicine pituitary section, is editor-in-chief of Pituitary, and is on the editorial board of Journal of Clinical Investigation and past Editor-in-Chief of Endocrinology. He served on NIH Endocrinology Study Section, was president and founding member of the Pituitary Society, member of Endocrine Society Council and President of International Society of Endocrinology. He is Program Chair of the International Congress of Endocrinology, and a Board Member of the California Institute of Regenerative Medicine (CIRM).

Audience Q&A

All

We thank our educational partners, CMM Global, Inc.

supported by:

Chiasma, Inc.

Learning Objectives:

Examine the main aspects of acromegaly, including scientific advances and expanding knowledge of disease pathogenesis, improvements in disease management, and new medical therapies (available and in development) to improve disease control
Establish familiarity with current research related to patient and medical provider reporting of symptoms during treatment
Enhance understanding of available treatment options and the consequent outcomes (i.e., control of GH/IGF-I levels, amelioration of signs/symptoms, improved QoL, ease of administration) associated with use of these different treatment options

Search